Seoul Pharma Statistics
Total Valuation
Seoul Pharma has a market cap or net worth of KRW 35.68 billion. The enterprise value is 43.22 billion.
| Market Cap | 35.68B | 
| Enterprise Value | 43.22B | 
Important Dates
| Earnings Date | n/a | 
| Ex-Dividend Date | n/a | 
Share Statistics
Seoul Pharma has 11.66 million shares outstanding.
| Current Share Class | 11.66M | 
| Shares Outstanding | 11.66M | 
| Shares Change (YoY) | n/a | 
| Shares Change (QoQ) | n/a | 
| Owned by Insiders (%) | n/a | 
| Owned by Institutions (%) | n/a | 
| Float | 4.73M | 
Valuation Ratios
| PE Ratio | n/a | 
| Forward PE | n/a | 
| PS Ratio | 0.68 | 
| PB Ratio | 0.92 | 
| P/TBV Ratio | 0.94 | 
| P/FCF Ratio | n/a | 
| P/OCF Ratio | n/a | 
| PEG Ratio | n/a | 
Enterprise Valuation
The stock's EV/EBITDA ratio is 18.62, with an EV/FCF ratio of -10.04.
| EV / Earnings | -65.40 | 
| EV / Sales | 0.83 | 
| EV / EBITDA | 18.62 | 
| EV / EBIT | n/a | 
| EV / FCF | -10.04 | 
Financial Position
The company has a current ratio of 1.99, with a Debt / Equity ratio of 0.46.
| Current Ratio | 1.99 | 
| Quick Ratio | 1.04 | 
| Debt / Equity | 0.46 | 
| Debt / EBITDA | 7.71 | 
| Debt / FCF | -4.16 | 
| Interest Coverage | -0.75 | 
Financial Efficiency
Return on equity (ROE) is -1.69% and return on invested capital (ROIC) is -0.38%.
| Return on Equity (ROE) | -1.69% | 
| Return on Assets (ROA) | -0.29% | 
| Return on Invested Capital (ROIC) | -0.38% | 
| Return on Capital Employed (ROCE) | -0.59% | 
| Revenue Per Employee | 303.46M | 
| Profits Per Employee | -3.84M | 
| Employee Count | 172 | 
| Asset Turnover | 0.74 | 
| Inventory Turnover | 1.58 | 
Taxes
| Income Tax | -84.70M | 
| Effective Tax Rate | n/a | 
Stock Price Statistics
The stock price has decreased by -21.20% in the last 52 weeks. The beta is 0.55, so Seoul Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.55 | 
| 52-Week Price Change | -21.20% | 
| 50-Day Moving Average | 3,218.70 | 
| 200-Day Moving Average | 3,331.35 | 
| Relative Strength Index (RSI) | 45.41 | 
| Average Volume (20 Days) | 8,367 | 
Short Selling Information
| Short Interest | n/a | 
| Short Previous Month | n/a | 
| Short % of Shares Out | n/a | 
| Short % of Float | n/a | 
| Short Ratio (days to cover) | n/a | 
Income Statement
In the last 12 months, Seoul Pharma had revenue of KRW 52.20 billion and -660.90 million in losses. Loss per share was -56.68.
| Revenue | 52.20B | 
| Gross Profit | 31.83B | 
| Operating Income | -329.39M | 
| Pretax Income | -745.60M | 
| Net Income | -660.90M | 
| EBITDA | 2.32B | 
| EBIT | -329.39M | 
| Loss Per Share | -56.68 | 
Balance Sheet
The company has 10.36 billion in cash and 17.90 billion in debt, giving a net cash position of -7.54 billion or -646.88 per share.
| Cash & Cash Equivalents | 10.36B | 
| Total Debt | 17.90B | 
| Net Cash | -7.54B | 
| Net Cash Per Share | -646.88 | 
| Equity (Book Value) | 38.68B | 
| Book Value Per Share | 3,317.27 | 
| Working Capital | 17.18B | 
Cash Flow
In the last 12 months, operating cash flow was -2.98 billion and capital expenditures -1.32 billion, giving a free cash flow of -4.31 billion.
| Operating Cash Flow | -2.98B | 
| Capital Expenditures | -1.32B | 
| Free Cash Flow | -4.31B | 
| FCF Per Share | -369.24 | 
Margins
Gross margin is 60.98%, with operating and profit margins of -0.63% and -1.27%.
| Gross Margin | 60.98% | 
| Operating Margin | -0.63% | 
| Pretax Margin | -1.43% | 
| Profit Margin | -1.27% | 
| EBITDA Margin | 4.45% | 
| EBIT Margin | -0.63% | 
| FCF Margin | n/a | 
Dividends & Yields
Seoul Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a | 
| Dividend Yield | n/a | 
| Dividend Growth (YoY) | n/a | 
| Years of Dividend Growth | n/a | 
| Payout Ratio | n/a | 
| Buyback Yield | n/a | 
| Shareholder Yield | n/a | 
| Earnings Yield | -1.85% | 
| FCF Yield | -12.07% | 
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a | 
| Lynch Upside | n/a | 
| Graham Number | n/a | 
| Graham Upside | n/a | 
Stock Splits
The last stock split was on April 12, 2004. It was a forward split with a ratio of 2.
| Last Split Date | Apr 12, 2004 | 
| Split Type | Forward | 
| Split Ratio | 2 | 
Scores
Seoul Pharma has an Altman Z-Score of 1.78 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.78 | 
| Piotroski F-Score | 1 |